U.S. Luxury Stock News

NasdaqGS:SHOP
NasdaqGS:SHOPIT

Shopify (SHOP), What Is Behind The Fresh Attention Around The Stock?

Recent attention on Shopify (NasdaqGS:SHOP) centers on AppLovin’s deeper integration into its commerce ecosystem, giving merchants more advertising tools fed by Shopify’s rich transaction data. That development arrives alongside continued billings and revenue growth indicators. See our latest analysis for Shopify. At a share price of US$149.25, Shopify’s recent 31.21% 1 month share price return and 42.28% 3 month share price return point to building momentum, even though the year to date...
NYSE:MCD
NYSE:MCDHospitality

McDonald's (MCD) Enters Energy Drinks Following Red Bull Launch As Fair Value Questions Linger

McDonald's (MCD) has started selling the Red Bull Dragonberry Energizer across U.S. restaurants, marking its first move into energy drinks. The launch targets younger customers and supports broader beverage and loyalty program goals. See our latest analysis for McDonald's. The new energy drink offer arrives while McDonald's shares trade at US$270.95. The stock has posted a 2.3% 30 day share price return but a weaker year to date share price return of 10.7%, and a 1 year total shareholder...
NYSE:INR
NYSE:INROil and Gas

Oil Stocks Outside The Middle East That Could Benefit From Hormuz Disruption

When shipping routes through the Strait of Hormuz and the Red Sea are at risk, attention shifts to oil and gas producers that might be less directly exposed to those chokepoints. This disruption can reshape where capital flows, who secures premium pricing and which stocks investors watch most closely. This article looks at 3 stocks from our Non Middle East Oil & Gas Producers screener that appear positively exposed to the latest news shock. The three stocks highlighted below are just a sample...
NYSE:ABBV
NYSE:ABBVBiotechs

Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates with manageable safety profiles. See our latest analysis for AbbVie. The latest lung cancer data arrives during a strong run for AbbVie, with a 24.32% 90 day share price return and a 31.62% 1 year total shareholder return suggesting that momentum has been building. If this lung cancer update has...
NasdaqGS:SGRY
NasdaqGS:SGRYHealthcare

How Mixed Q2 Results and Slower M&A At Surgery Partners (SGRY) Have Changed Its Investment Story

In August 2026, Surgery Partners, Inc. reported second-quarter 2026 results showing sales of US$848.9 million versus US$826.2 million a year earlier, alongside a higher net loss of US$15.0 million, while also disclosing no share repurchases under its March 2026 buyback authorization to date. Management highlighted that disciplined M&A and portfolio optimization have led to only an immaterial level of acquisitions so far in 2026, and that total M&A spending will fall short of its US$200.0...
NYSE:FNB
NYSE:FNBBanks

Is F.N.B (FNB) Undervalued As It Expands Private Family Wealth?

F.N.B (FNB) has expanded its Private Family Wealth offering for ultra high net worth clients by adding specialized advisory services and advanced solutions that aim to support long term and multigenerational financial objectives. See our latest analysis for F.N.B. F.N.B's recent move to build out Private Family Wealth comes as the stock shows mixed momentum, with the 7 day share price return declining 4.5%, the 90 day share price return rising 5.1%, and the 1 year total shareholder return at...
NasdaqGS:ROP
NasdaqGS:ROPSoftware

Roper Technologies (ROP) Adds PayPal And Venmo To Illumia, Is It Still 8% Undervalued?

Roper Technologies (ROP) drew attention after its Illumia education platform introduced PayPal and Venmo as tuition payment options. This client announcement raises fresh questions about the company’s software driven recurring revenue profile. See our latest analysis for Roper Technologies. The Illumia payment update lands during a period of mixed performance for Roper Technologies, with a 90 day share price return of 28.56% and a year to date share price decline of 5.24%, while the 1 year...
NYSE:BAX
NYSE:BAXMedical Equipment

How Baxter’s Finance Leadership Overhaul and Debt Moves Will Impact Baxter International (BAX) Investors

Baxter International has recently appointed John Rogers as Chief Financial Officer and Executive Vice President, adjusted its credit agreement to allow higher net leverage, and expanded its bond tender offer capacity to US$600 million while also naming an interim Chief Accounting Officer and Controller. Together, the leadership refresh in Baxter’s finance organization and the move to repurchase long-dated debt signal a concerted effort to reshape its balance sheet and tighten financial...
NasdaqGS:NTCT
NasdaqGS:NTCTCommunications

How Investors May Respond To NetScout Systems (NTCT) Expanding DDoS Protection Beyond Traditional CDN Defenses

Earlier in August 2026, NETSCOUT announced upgrades to its Arbor Edge Defense and Adaptive DDoS Protection platforms to help enterprises and service providers identify and block sophisticated DDoS attacks that evade traditional CDN defenses and originate from compromised IoT devices. By restoring visibility into traffic hidden behind shared CDN infrastructure and extending protection to outbound service-provider traffic, NETSCOUT is targeting a critical blind spot where application...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

CME Group (CME) Has Investors Asking A Bigger Question

CME Group (CME) has drawn fresh attention after outlining three new futures initiatives in sports, compute and metals that expand its product set and around the clock trading access for different customer types. See our latest analysis for CME Group. For context, CME Group's 1-month share price return of 7.70% and 7-day share price return of 2.65% suggest momentum has picked up again after a 90-day period when the share price declined 2.68%. The 5-year total shareholder return of 70.23%...
NasdaqGM:CDNA
NasdaqGM:CDNABiotechs

Is CareDx’s AI and EHR Push Reshaping Its Role In Transplant Care Infrastructure (CDNA)?

Recent developments at CareDx highlight its growing role in precision medicine and transplant care, underpinned by AI-driven diagnostics such as AlloSure Plus and deeper integration into electronic health record systems. These moves point to CareDx increasingly positioning itself as an infrastructure provider for personalized transplant monitoring, rather than just a single-test diagnostics vendor. We’ll now explore how this push into AI-driven diagnostics and EHR integration may influence...
NYSE:MYE
NYSE:MYEPackaging

Carrier Stock And 2 US Industrial Picks For Canada Tariff Substitution

Tariffs between the US and Canada are no longer just headlines; they are starting to reshape where factories run, where goods are sourced and which companies sit closer to the front of the line when trade costs rise. That shift can create fresh winners and leave others lagging. This article walks through three stocks exposed to this trade story and explains why each could matter for your portfolio decisions today. The three stocks covered below are just a starting sample, and the full screen...
NYSE:VNO
NYSE:VNOOffice REITs

Vornado Realty Trust (VNO) Lands 350 Park Avenue Venture As Valuation Debate Stays Open

Vornado Realty Trust (VNO) has agreed to a joint venture with Rudin Management and an affiliate of Kenneth C. Griffin to develop a 1.9 million square foot office tower at 350 Park Avenue. See our latest analysis for Vornado Realty Trust. The joint venture announcement comes as Vornado Realty Trust trades at US$37.88, with the share price down 4.63% over the past month but up 15.84% over 90 days and supported by a 71.16% three year total shareholder return. This points to momentum building...
NYSE:OWL
NYSE:OWLCapital Markets

3 Private Credit Stocks Facing Higher Rate Pressure

With U.S. public debt above US$40t, long term yields over 5% on the 30 year and no strong policy stimulus in sight, funding costs are becoming a story investors can no longer ignore. Higher discount rates can reshape which stocks benefit from this capital hungry cycle and which struggle. This article walks through three stocks from the private credit and direct lending screener that look particularly exposed to these forces. The three stocks below are just a starting sample, and the full...
NYSE:VZ
NYSE:VZTelecom

What Verizon Communications (VZ)'s Google Cloud AI Push and Pixel 11 Strategy Means For Shareholders

In recent weeks, Verizon Communications said it will redeem all of its US$1.25 billion 4.329% Notes due 2028 on September 21, 2026, while also rolling out an exclusive Google Pixel 11 lineup with new Simplicity and Simplicity Pro wireless plans and aggressive device promotions. These moves, combined with a new Google Cloud AI partnership to modernize customer experiences and network intelligence, highlight Verizon’s push toward AI-powered, value-focused connectivity services. We’ll now...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Eli Lilly (LLY) has moved further into obesity and diabetes care with the UK launch of its once daily oral GLP-1 pill Foundayo, orforglipron, shortly after lifting its full year outlook. See our latest analysis for Eli Lilly. The launch of Foundayo comes during a strong run for Eli Lilly’s stock, with a 90 day share price return of 17.91% and a 1 year total shareholder return of 81.69%. This indicates momentum that has built rather than faded over multiple years. If you are interested in how...
NYSE:ASA
NYSE:ASACapital Markets

ASA Gold And Precious Metals (ASA) Faces Governance Questions, Is It Still A Bargain?

Governance concerns come into focus for ASA Gold and Precious Metals On 14 August 2026, investor Alexander Merk filed an exempt solicitation with the SEC that challenges ASA Gold and Precious Metals (NYSE:ASA) board expertise and its approach to shareholder rights. Merk also released a dashboard that tracks key company metrics since the board took over management on 1 July 2026, while highlighting that current overseers reportedly lack precious metals mining experience. See our latest...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders

Cogent Biosciences, Inc. reported past earnings results for the second quarter and six months ended June 30, 2026, with net losses of US$96.41 million for the quarter and US$193.76 million for the half-year, both higher than the prior year. The widening losses highlight the company’s growing investment in its operations and development efforts, a key consideration for investors assessing its progress. Next, we’ll examine how the widening net losses shape Cogent Biosciences’ investment...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Arm Holdings (ARM) AI Push Puts Fair Value Back In Focus

Arm Holdings (NasdaqGS:ARM) is back in focus after recent fund letters highlighted its latest quarter, which showed 20% revenue growth and 12% profit growth, along with increasing exposure to AI and data center workloads. See our latest analysis for Arm Holdings. Arm Holdings has seen short term share price momentum cool, with the share price down 10.36% over the last week and 24.25% over 90 days, even after a very strong 112.08% year to date share price return and a 76.60% total shareholder...
NYSE:PRU
NYSE:PRUInsurance

3 Insurance Stocks Retail Investors Are Eyeing as Treasury Yields Stay High

With the 10 year U.S. Treasury yield near 4.73% and the 30 year at multi year highs, long term rates are suddenly front and center for anyone watching life insurers and annuity providers. Rising yields, fresh Treasury buyback plans, sticky inflation above 3%, and the Iran conflict are reshaping the risk reward trade off. This article walks through 3 stocks exposed to these news drivers and how each might react. The 3 stocks below are just a starting sample from this theme, and the full screen...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

Is LivaNova (LIVN) Fairly Valued As Growth Hopes Meet Reimbursement Risks?

LivaNova (LIVN) has drawn investor attention after recent share price moves, with the stock last closing at $78.74. That places the company’s market value near $4.34b in the medical technology space. See our latest analysis for LivaNova. Recent trading has been choppy for LivaNova, with a 0.68% 1 day share price return and a 3.36% 7 day share price decline. However, the 29.85% year to date share price return and 39.73% 1 year total shareholder return point to momentum that has been building...
NasdaqGS:LI
NasdaqGS:LIAuto

Li Auto (LI) Updates Mega As Its BEV Narrative Points To Higher Fair Value

Li Auto (NasdaqGS:LI) is in focus after unveiling an updated Mega minivan that keeps its bullet train inspired profile while adding fully active suspension, a larger 108 kWh battery, and expanded LiDAR coverage. See our latest analysis for Li Auto. For investors tracking Li Auto, the recent product update arrives as the share price shows mixed momentum, with a 7.67% 1 month share price return and a year to date share price decline of 24.35%, alongside a 1 year total shareholder return decline...
NYSE:EXR
NYSE:EXRSpecialized REITs

Is Extra Space Storage (EXR) Fairly Valued As It Prepares For A CEO Transition?

Extra Space Storage (EXR) has drawn fresh attention after announcing that President Noah Springer will become chief executive officer on January 1, 2027, as long-serving CEO Joe Margolis retires and moves into an advisory role. See our latest analysis for Extra Space Storage. Despite the leadership news and a recently affirmed quarterly dividend, Extra Space Storage’s recent share price has been relatively steady. The 90 day share price return of 1.96% sits against a stronger year to date...
NYSE:UAA
NYSE:UAALuxury

Under Armour (UAA), What Is Behind Its Latest Update?

Under Armour (UAA) recently highlighted contrasting trends, with international regions such as Europe, the Middle East and Africa and Latin America reporting growth that helped counter softer North American demand, while management cut FY2027 guidance to a mid single digit decline in revenue. See our latest analysis for Under Armour. The recent guidance cut appears to have weighed on sentiment, with a 30 day share price return of down 23.33% and a 90 day share price return of down 4.77% even...